AUSTIN, Texas, June 8, 2015 /PRNewswire/ -- Luminex Corporation
(NASDAQ: LMNX) today announced that it has commenced clinical and
analytical studies to evaluate the company's ARIES™ Group B
Streptococcus (GBS) Assay.
"We continue to build momentum in our commercial launch schedule
for the ARIES platform with the start of clinical trials for GBS,
the third assay in the ARIES pipeline," said Homi Shamir, President and CEO of Luminex. "The
progression of our ARIES menu with assays that are important to
patient care continues and the Group B Strep assay is a key
contributor due to the high prevalence and potentially serious or
life threatening consequences to newborns."
The clinical trials for the ARIES GBS Assay are being conducted
at several clinical laboratories in the U.S., and Luminex still
expects its FDA submission for the ARIES platform and ARIES HSV
1&2 Assay to occur in the summer of 2015.
About Group B Streptococcus (GBS)
One in four pregnant women are colonized with Group B
Streptococcus (GBS), also known as Streptococcus
agalactiae. If not treated, GBS can be transmitted to a newborn
during labor and delivery, potentially resulting in sepsis,
pneumonia, or meningitis. Fortunately, most GBS infections can be
prevented through recommended prenatal screening and, if positive,
administration of antibiotic treatment during
delivery.1
About ARIES
ARIES is a sample to answer system designed to deliver superior
laboratory performance, increase laboratory efficiency, and fit
seamlessly into today's lean laboratory environment. ARIES uses
internal barcode scanning and other advanced features to minimize
operator errors. Two independent magazine modules support from one
to six cassettes each, allowing for STAT and Batch testing.
Simultaneous IVD and Laboratory Developed Tests (LDTs) operate
through a common Universal Assay Protocol. An integrated PC
eliminates the need for a separate computer, stand-alone keyboard,
and mouse, thus maximizing valuable bench space.
To learn more or request a demo, visit:
http://www.luminexcorp.com/ARIES
About Luminex Corporation
Luminex is committed to applying its passion for innovation
toward creating breakthrough solutions to improve health and
advance science. The company is transforming global healthcare and
life-science research through the development, manufacturing and
marketing of proprietary instruments and assays utilizing xMAP®
open-architecture multi-analyte platform, MultiCode® real-time
polymerase chain reaction (PCR), and multiplex PCR-based
technologies, that deliver cost-effective rapid results to
clinicians and researchers. Luminex's technology is commercially
available worldwide and in use in leading clinical laboratories, as
well as major pharmaceutical, diagnostic, biotechnology, and life
science companies. Luminex is meeting the needs of customers in
markets as diverse as clinical diagnostics, pharmaceutical drug
discovery, biomedical research including genomic and proteomic
research, personalized medicine, biodefense research and food
safety. For further information on Luminex Corporation and the
latest advances in multiplexing using award winning technology,
please visit http://www.luminexcorp.com/.
Statements made in this release that express Luminex's or
management's intentions, plans, beliefs, expectations or
predictions of future events are forward-looking statements.
Forward-looking statements in this release include statements
regarding the development and testing progress of our pipeline
products, including ARIES and related assays, and the regulatory
approvals thereof. The words "believe", "expect", "intend",
"confident", "will", "could", "should", and similar expressions are
intended to further identify such forward-looking statements for
purposes of the Private Securities Litigation Reform Act of 1995.
It is important to note that the Company's actual results or
performance could differ materially from those anticipated in such
forward-looking statements. Factors that could cause Luminex's
actual results or performance to differ materially include risks
and uncertainties relating to, among others, our ability to launch
products on time, the timing of regulatory approvals, the outcome
of clinical trials as well as the risks discussed under the heading
"Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as
filed with the Securities and Exchange Commission. The
forward-looking statements contained herein represent the judgment
of Luminex as of the date of this press release, and Luminex
expressly disclaims any intent, obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements to reflect any change in Luminex's expectations with
regard thereto or any change in events, conditions or circumstances
on which any such statements are based.
References:
1. About Group B Strep. Centers for Disease Control and
Prevention (Internet). Cited 2015 June. Available from:
http://www.cdc.gov/groupbstrep/about.
Contacts:
Luminex Investor Contact
Harriss Currie, 512.219.8020
Sr. Vice President of Finance and CFO
hcurrie@luminexcorp.com
Luminex Media Contact
Christine Valle, 512.219.8020
Sr. Manager, Global Marketing
cvalle@luminexcorp.com
Photo - http://photos.prnewswire.com/prnh/20150608/221405
Logo - http://photos.prnewswire.com/prnh/20150201/172702LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/luminex-corporation-begins-clinical-trials-for-aries-gbs-assay-300095514.html
SOURCE Luminex Corporation